SCHEMBL1342277

SCHEMBL1342277

Cc1ccc(NC(=O)C(=O)Nc2nc(CNS(C)(=O)=O)c(Br)s2)c(C(=O)C2CCCC2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 2/20 0.35
ABCC1 P33527 1/20 0.35
KMT2A Q03164 3/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 6/20 0.34
LMNA P02545 4/20 0.34
MEN1 O00255 2/20 0.34
ACP1 P24666 1/20 0.33
TP53 P04637 3/20 0.33
MAPK1 P28482 2/20 0.33
HTT P42858 2/20 0.33
ALOX12 P18054 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
PTPN1 P18031 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CG P48736 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1342250 0.93 ABCC1 (0.35) CLK1ABCC1KMT2ANPC1RAB9A
SCHEMBL1342521 0.92 NPC1 (0.38) CLK1ABCC1KMT2ANPC1RAB9A
SCHEMBL1341936 0.90 CLK1 (0.37) CLK1ABCC1KMT2ANPC1RAB9A
SCHEMBL1341933 0.90 PIK3CD (0.36) CLK1ABCC1KMT2AGAAMAPT
SCHEMBL1341818 0.89 RORC (0.36) CLK1KMT2ANPC1RAB9AGAA
SCHEMBL6696138 0.89 MAPT (0.36) KMT2ANPC1RAB9AMAPTMEN1
SCHEMBL1342883 0.89 CLK1 (0.34) CLK1ABCC1KMT2ANPC1RAB9A
SCHEMBL1343720 0.84 GAA (0.34) CLK1KMT2ARAB9AGAAMAPT
SCHEMBL1340521 0.84 TP53 (0.38) CLK1KMT2ANPC1RAB9ALMNA
SCHEMBL1342119 0.83 CLK1 (0.37) CLK1ABCC1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 CLK1 582/4885ABCC1 1031/4885KMT2A 1526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.